UM LAPs - UG1 Grant

项目摘要 密歇根大学（UM），包括其综合癌症中心（UMCCC）和 医学院部门，要求这个UG 1奖作为NCI国家临床试验 网络领导学术参与网站（NCTN LAPS-UG 1）。我们将此机会视为 是我们机构大型癌症研究工作的重要组成部分。我们仍然致力 多机构合作对癌症的发展至关重要 治疗我们作为LAPS网站的目标是使重大的科学，领导，行政 和患者数据的贡献，NCTN努力研究和改善癌症治疗。的 NCTN过程包括开发和进行有目的的临床试验，采用 统一的毒性和反应标准，收集患者数据和结果报告。NCTN 小组研究是唯一的设置，其中复杂的概念，结合模态和 可以适当地评估跨学科疗法以及辅助疗法。NCTN临床 研究还提供了一个更好的理解之间的重要关系， 预后因素、治疗和患者结局，否则无法获得。

PROJECT SUMMARY The University of Michigan (UM), inclusive of its Comprehensive Cancer Center (UMCCC) and Medical School Departments, requests this UG1 award as an NCI National Clinical Trials Network Lead Academic Participating Site (NCTN LAPS-UG1). We view this opportunity as an important component of a large cancer research effort at our institution. We remain committed to the concept that multi-institutional collaboration is essential to the advancement of cancer treatment. Our goal as a LAPS site is to make significant scientific, leadership, administrative and patient data contributions to the NCTN effort to study and improve cancer therapy. The NCTN process involves the development and conduct of purposeful clinical trials, adoption of uniform toxicity and response criteria, collection of patient data, and results reporting. NCTN Group research is the only setting in which sophisticated concepts of combined modality and interdisciplinary therapy as well as adjuvant therapies can be properly evaluated. NCTN clinical research has also provided an improved understanding of the important relationships between prognostic factors, therapy and patient outcomes that could not have been obtained otherwise.